Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Lifecore Biomedical (LFCR) over the last 2 years, with May 2011 value amounting to $206.3 million.

  • Lifecore Biomedical's Cash & Equivalents fell 2.33% to $8.3 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 2.33%. This contributed to the annual value of $8.3 million for FY2025, which is 2.33% down from last year.
  • As of Q2 2025, Lifecore Biomedical's Cash & Equivalents stood at $8.3 million, which was up 52.58% from $5.4 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Cash & Equivalents ranged from a high of $19.1 million in Q2 2023 and a low of $609,000 during Q4 2021.
  • Over the past 3 years, Lifecore Biomedical's median Cash & Equivalents value was $8.4 million (recorded in 2024), while the average stood at $8.9 million.
  • Data for Lifecore Biomedical's Revenue - Interest and Investment Income shows a peak YoY spiked of 157,650.18% (in 2011) over the last 5 years.
  • Quarterly analysis of 3 years shows Lifecore Biomedical's Revenue - Interest and Investment Income stood at $160.4 million in 2009, then grew by 29.07% to $207.0 million in 2010, then soared by 157,650.18% to $206.3 million in 2011.
  • Its Cash & Equivalents stands at $8.3 million for Q2 2025, versus $5.4 million for Q1 2025 and $9.5 million for Q4 2024.